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ABSTRACT
Background—There is increasing interest in zero coronary artery calcium 
(CAC) as a marker of sustained good health. The long-term associations 
between zero and minimal CAC and cause-specific mortality are currently 
unknown, particularly after accounting for competing risks with other causes 
of death.
Methods and Results—We evaluated 66,363 apparently healthy 
individuals from the CAC Consortium multi-center, observational, 
retrospective cohort study. Cohort entry expanded through 1991–2010 and 
follow-up information was obtained through 2014. All patients had CAC 
measured at baseline for clinical risk assessment, and were followed over 
mean 12 years for all-cause and cause-specific mortality, including coronary 
heart disease (CHD), cardiovascular disease (CVD) and cancer death. 
Patients with CAC=0 (45% prevalence) had stably low rates of CHD death, 
CVD death (ranging 0.32 to 0.43 per 1,000 person-years), and of all-cause 
death. Cancer was the predominant cause of death in this group ranging 
0.47 to 0.79 per 1,000 person-years. Patients with CAC 1-10 had greater 
crude incidence of deaths from CHD and CVD, although multivariable-
adjusted Fine and Gray competing risk regression models demonstrated a 
persistent relationship with CVD mortality (as compared to CAC=0) only 
under age 40. Patients with CAC>10 had multivariable-adjusted increased 
risks of CHD, CVD and all-cause mortality, and a greater proportion of deaths
due to CVD. 
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Conclusions—Zero CAC, which is a frequent finding in patients undergoing 
clinical CAC scanning in the US, is associated with stably low rates of CVD 
mortality over 12-year follow-up. In this group of healthy agers, cancer is the 
predominant cause among the infrequent deaths. Our results support the 
emerging consensus that CAC=0 represents a unique population with highly 
favorable all-cause prognosis, who may be considered for more flexible 
treatment goals in primary prevention. 
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ABBREVIATIONS AND ACRONYMS
ACC/AHA American College of Cardiology / American Heart Association
CAC coronary artery calcium
CHD coronary heart disease
CI confidence interval
CT computed tomography
CVD cardiovascular disease
ICD International Classification of Diseases
MESA Multi-Ethnic Study of Atherosclerosis
SD standard deviation
SHR subdistribution hazard ratios
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TEXT
Introduction
There is increasing interest in zero coronary artery calcium (CAC) as a 
marker of sustained good health.1,2 Prior studies have suggested very low 10-
year rates of coronary heart disease (CHD) events, cardiovascular disease 
(CVD) events, and all-cause mortality in the presence of a CAC score of zero 
(CAC=0).3–12 Indeed, CAC=0 appears to be the single strongest “negative risk
factor” for incident CVD.13 Consistent with this, recent guidelines from the 
American College of Cardiology and the American Heart Association 
(ACC/AHA) have assigned CAC a preeminent role in CVD risk assessment and
endorse CAC=0 as a powerful marker of decreased CVD risk.14
Intriguingly, recent reports have also linked the absence of CAC with 
low rates of cancer and other non-CVD events such as incident chronic 
obstructive lung disease, chronic kidney disease, hip fracture, and 
dementia.15 This has led to the hypothesis that the absence of CAC may be a 
marker of healthy “biologic aging”. Supporting this view, even minimal CAC 
(Agatston scores of 1–10 units) have been associated with higher CVD events
and all-cause mortality.9,10
However, there is little data available on the long-term associations of 
CAC=0, CAC 1-10, and higher CAC particularly after accounting for 
competing risks of cause-specific mortality. Currently, the predominant 
cause of infrequent death in those with CAC=0 is unknown, and the impact 
7
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
1
2
of increasing CAC scores on CVD versus non-CVD causes of death remains 
unclear, as well as the potential impact of age and sex on these 
relationships.
Given the complicated association of CAC with risk of multiple 
diseases, we sought to conduct a competing risk analysis studying zero and 
minimal CAC within the CAC Consortium, a large cohort with long-term 
follow-up for cause-specific death.16 Such data may be important for 
estimating prognosis and informing preventive strategies in patients at the 
low end of the risk spectrum.
Methods
The CAC Consortium
The characteristics of the CAC Consortium have been described 
elsewhere.16–18 Briefly, this is a multi-center, retrospective cohort study of 
66,636 consecutive patients undergoing routine clinical CAC scoring for CVD 
risk assessment in 4 high volume US centers. Patients were free of overt CVD
or of clinically important CVD symptoms (i.e. typical angina or angina-
equivalent) at cohort entry, which was defined by the time of the baseline 
CAC examination. Baseline data – including demographic characteristics, 
cardiovascular risk factors, and baseline CAC scores – was obtained at cohort
entry through 1991 – 2010, and follow-up information was obtained through 
June 2014. 
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Prior analyses have shown that the baseline characteristics of the CAC 
Consortium population are similar to those of well-characterized, 
contemporary US cohorts such as NHANES 2001-2002, Framingham 
Offspring, and others.16 
Research Ethics
Written informed consent for participation in research was collected at 
all centers prior to the baseline CAC scanning. Institutional review board 
approval for coordinating center activities including death ascertainment and
death certificate collection was obtained at the Johns Hopkins Hospital 
(Baltimore, Maryland, USA).
Study Population
For the present analysis, all 66,363 patients from the CAC Consortium 
were included. Participants were categorized into three groups: CAC=0, 
minimal CAC (1-10), and CAC>0. 
Baseline Evaluation
As described above, all patients in the CAC Consortium underwent a 
baseline computed tomographic (CT) scan. This included both patients 
scanned using electron beam tomography (93%), as well as in later years, 
patients scanned using multi-detector CT (7%). A common standard non-
contrast cardiac-gated CT scanning protocol was used across sites, adapted 
to each CT scanner technology. CAC was scored using the Agatston 
method.19 
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In each center, data on self-reported cardiovascular risk factors, 
treatment use, and laboratory test results was collected as part of the 
routine clinical visit associated with the referral for CAC testing and/or from a
semi-structured in-person interview. Details on the definitions used in the 
CAC Consortium for each cardiovascular risk factor have been described 
elsewhere,16-18 and are summarized in the Supplementary Methods 
section of the online Supplementary Appendix. For each participant, 10-year 
atherosclerotic CVD risk was estimated using the Pooled Cohort Equations 
following current ACC/AHA guideline recommendations.14 
Event Definitions and Ascertainment
The 4 primary outcomes for the present study were all-cause, CHD, 
CVD and cancer mortality, all assessed over mean 12 years follow-up 
(standard deviation [SD] 4 years, maximum follow-up across the 4 sites 
ranging from 13.6 to 22.5 years). Secondary study outcomes included stroke 
mortality, heart failure mortality, other circulatory disorder mortality (non-
CHD, non-stroke), total non-CVD mortality (death from all causes except for 
CVD), and pulmonary mortality.
In the CAC Consortium, mortality was assessed via linkage of patient 
records with the Social Security Administration Death Master File using a 
previously validated algorithm. Death certificates were obtained from the 
National Death Index, and the underlying cause of death was categorized 
into common causes of death using the International Classification of 
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Diseases version 9 (ICD-9) and version 10 (ICD-10) codes as previously 
described.  
Statistical Analyses
Baseline characteristics of the study participants were described 
overall and by three baseline CAC strata: CAC=0, CAC 1-10, and CAC>10. 
Number and proportion were used to summarize categorical variables, and 
mean ± SD or median and interquartile range were used for continuous 
variables depending on the normality of the data. Chi-square, ANOVA and 
Kruskal-Wallis tests were used for statistical comparisons across CAC groups 
as appropriate.
The cumulative incidence (incidence proportion, expressed in %) of all-
cause and cause-specific death was calculated both overall as well as by 
baseline CAC burden. The proportion of deaths due to specific causes was 
also computed for each CAC strata, by dividing the number of cause-specific 
deaths by the total number of deaths observed in each group. All-cause and 
cause-specific incident mortality rates during follow-up were also calculated 
and expressed per 1,000 patient-years. These results were displayed 
graphically for assessment of trends over the course of follow-up.
Multivariable Cox proportional hazards regression models were used to
assess the multivariable-adjusted associations between increasing baseline 
CAC burden (CAC 1-10 and CAC>10, respectively, compared to CAC=0) and 
all-cause mortality. In addition, for cause-specific death endpoints, 
competing risks regression using Fine and Gray models20 were used to 
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examine the associations between CAC and CHD death, CVD death, and 
cancer death, respectively, accounting for competing risks with other causes 
of death. Results for the competing risks regression analyses are presented 
using subdistribution hazard ratios (SHR) with 95% confidence intervals (CI).
For all regression analyses, three hierarchical multivariable models 
were built with increasing levels of adjustment. Model 1 was unadjusted, 
Model 2 adjusted for age and sex, and Model 3 further adjusted for 
hypertension, current smoking, diabetes, dyslipidemia, and family history of 
CHD. In a sensitivity analysis we further adjusted for race/ethnicity, which 
was known for only 65% of the study participants included in the CAC 
Consortium. 
Subgroup analyses were also conducted, stratifying by sex and age 
strata. Finally, exploratory analyses were also conducted, assessing the 
multivariable-adjusted associations between CAC categories and other 
relevant causes of death: stroke death, heart failure death, other circulatory 
disease death, any non-CVD death, and pulmonary death. 
All analyses were conducted using Stata version 15.21 A threshold of p 
<0.05 was used to define statistical significance.
Results
Baseline Characteristics
The mean age of the 66,363 patients included in the study was 54.5 
years (SD 10.6), 33% were women, and the vast majority (89.1%) were non-
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Hispanic Whites (Table 1). Dyslipidemia was the most prevalent 
cardiovascular risk factor (56.8%), while diabetes was the least (6.8%). The 
median estimated 10-year ASCVD risk was 4.4% (interquartile range 1.9 – 
9.2). 
At study baseline 29,575 (44.7%) patients had CAC=0, 7,808 (11.7%) 
had CAC 1-10, and 29,071 (43.6%) had CAC>10. Patients with higher CAC 
scores were significantly older, more likely to be male, had a greater burden 
of traditional CVD risk factors, and had a higher average 10-year estimated 
ASCVD risk. 
Incident Death Events during Follow-Up
Over a 12-year mean follow-up, 3,158 deaths occurred, including 524 
CHD deaths, 971 CVD deaths, and 1,129 cancer deaths. The lowest all-cause 
and cause-specific mortality risks were observed in patients with CAC=0 
(0.17% for CHD mortality, 0.41% for CVD mortality, and 0.97% for cancer 
mortality) (Figure 1). Risks of death were slightly higher for patients in the 
CAC 1-10 group, and substantially higher for those with CAC>10. 
Cause of Death
Cancer death was more frequent than CVD death in both CAC=0 and 
CAC 1-10 patients, while the opposite was true for CAC>10 patients (Figure 
1). Specifically, among the 595 deaths occurring in the CAC=0 group, the 
predominant cause of death was cancer (288, 48% of total), while only 51 
(9%) and 121 (20%) of deaths were due to CHD and CVD, respectively 
(Figure 2, Panel A). The proportion of deaths due to CHD and CVD both 
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increased with increasing CAC scores, while the proportion of cancer deaths 
decreased (Figure 2, Panels B and C).
Trends in All-Cause and Cause-Specific Death Rates over Time
In patients with CAC=0, cumulative incidence rates of all-cause death 
were stably low over time and were the lowest across all study groups, 
ranging 1.38 to 1.62 per 1,000 person-years (Figure 3 Panel A). Event 
rates were slightly higher in patients with CAC 1-10 (Panel B), although the 
highest rates were observed in patients with CAC >10—approximately 4-fold 
higher than those of CAC=0 patients. 
Figure 4 displays the cumulative incidence rates of CVD death and 
cancer death. In both patients with CAC=0 and CAC>0, there was a 
progressive decline in the cumulative rates of CVD death over time, the 
larger absolute decreases observed in patients CAC>0 and the largest 
relative decreases in those with CAC=0. In parallel, there was a progressive 
increase in the incidence of cancer death rates in both study groups. 
Specifically, in patients with CAC=0, at the end of follow-up cancer death 
rates were roughly 2.4-fold those for CVD death.
Associations between Baseline CAC Burden, All-Cause and Cause-Specific 
Mortality
In unadjusted analyses, compared to patients with CAC=0, those with 
CAC 1-10 had a 1.4-fold increased risk of death from any cause during follow-
up, while those with CAC>10 had a 4-fold increased risk (Table 2). After 
adjusting for traditional risk factors, there was no longer an independent 
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association between CAC 1-10 and all-cause death, while patients with 
CAC>10 still had a 1.6-fold multivariable-adjusted increased risk of all-cause 
death compared to those with CAC=0.
In competing risk analyses, there were strong multivariable-adjusted 
associations between CAC>10 (as compared to CAC=0) with both CVD death
(SHR 2.31, 95% CI 1.88, 2.85) and CHD death (SHR 2.31, 95% CI 1.88, 2.85). 
On the other hand, the association between CAC>10 and cancer death was 
much weaker (SHR 1.19, 95% CI 1.02, 1.40). For CAC 1-10, all 95% CIs 
included 1.00.
In sensitivity analyses within the subgroup with available race/ethnicity
data, further adjustment for race/ethnicity did not significantly alter the 
results (data not shown).
Subgroup Analyses
Generally similar results were observed in analyses stratified by sex 
(Table 3). Nonetheless, the multivariable-adjusted associations between 
CAC>10 (as compared to CAC=0) and all-cause death, CVD death, and 
cancer death were all numerically stronger in women, while the association 
with CHD death was stronger in men. 
In analyses stratified by age, the strongest associations between 
CAC>10 (as compared to CAC=0), all-cause death, CVD death, and cancer 
death were observed in the <40 years age stratum (Table 4). Very strong 
associations were also observed between CAC 1 – 10 (as compared to 
CAC=0), all-cause and CVD death in individuals <40 years. Conversely, 
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associations tended to be progressively weaker in  age strata defined by 
increasing age. 
Exploratory Analyses
Supplementary Table S1 shows the results of competing risk 
multivariable regression analyses for other pertinent outcomes. Compared to
CAC=0, CAC>10 was associated with a significantly greater risk of all causes
of death evaluated including stroke, heart failure, other circulatory disease, 
total non-CVD death, and pulmonary death. Very strong multi-variable 
adjusted associations were also observed between CAC 1-10 (as compared 
to CAC=0), heart failure death and pulmonary death, although for the former
outcome the 95% CIs were wide.    
Discussion
In the first large competing risks analysis of zero and minimal CAC and 
long-term cause-specific death, including 66,363 apparently healthy 
individuals undergoing clinical CAC scanning, we demonstrated that patients 
with CAC=0 (representing 45% of the study population) had stably low rates 
of CHD death, CVD death and all-cause death over 12-year follow-up. Cancer 
was the predominant cause of death in this group of healthy agers. While 
patients with CAC 1-10 had a greater crude incidence of deaths from CHD 
and CVD, multivariable-adjusted competing risk models demonstrated a 
persistent relationship with increased CVD mortality (as compared to CAC=0)
only in patients <40 years old. Participants with CAC>10 had multivariable-
16
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
1
2
adjusted increased risks of CHD, CVD and all-cause mortality compared to 
those with CAC=0, with a greater proportion of deaths due to CVD vs. non-
CVD causes in these individuals. These findings have implications for the 
allocation of preventive resources, particularly in patients at the low end of 
the risk spectrum.
Our results extend the work of prior studies examining the association 
of zero CAC, minimal (i.e., 1 – 10) CAC, and all-cause mortality. Our group 
previously demonstrated a very low death rate of approximately 0.5% over 5
years in a subset of CAC Consortium patients with CAC=0.3 More recently, 
Valenti et al also found a very low mortality rate in asymptomatic patients 
with CAC=0 undergoing CAC scoring in a single Tennessee center extending 
to 15-year follow-up.4 However, these two prior studies were limited by use 
of all-cause mortality as the only study outcome. Our present analysis adds 
to the existing literature by showing that in CAC=0 patients undergoing 
clinical CAC scanning for risk assessment purposes, death from any cause is 
a rare event at 12 years of follow-up, that CHD and CVD deaths are both very
infrequent, and that cancer is the leading cause of death in this overall 
healthy group. 
Our observations are also consistent with prior work showing low risk 
of CHD and CVD events in patients with CAC=0. For example, Budoff et al 
observed very low risk of CHD events amongst MESA participants from the 
Multi-Ethnic Study of Atherosclerosis (MESA), with 3-fold higher event rates 
in those with minimal CAC 1-10.9 Silverman et al. demonstrated very low 
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rates of percutaneous coronary intervention and coronary artery bypass 
surgery over 8.5 years of follow-up amongst individuals with CAC=0 in 
MESA.11 Expanding on non-CHD CVD endpoints, Gibson et al previously also 
demonstrated a low risk of stroke in MESA participants with zero CAC.12  
The present results provide further support to recent US clinical 
practice guideline recommendations, which in recent years have given 
increasing recognition to the “power of zero”.22 This includes the 2017 
guidelines from the Society of Cardiovascular Computed Tomography,23 
which articulated CAC=0 as a clinically actionable result, driving an 
enhanced clinician-patient risk discussion, with potential for selecting more 
flexible preventive treatment goals amongst these very low risk patients. 
Subsequently, the 2018 and 2019 ACC/AHA cardiovascular prevention 
guidelines brought CAC=0 to the forefront as a highly valuable tool for ‘de-
risking’ patients who would otherwise be considered candidates for chronic 
statin therapy.14,24 The fact that in our cohort almost half of the participants 
had a CAC score of zero (which is consistent with reports from other cohorts3-
10,25) supports the potential value of actively screening for CAC=0, at least in 
a broad intermediate risk group.  
Although cancer was the predominant cause of death in patients with 
CAC=0, death from cancer and from any other cause was a rare event during
12 years of follow-up in this healthy subgroup. Ours is not the first study to 
describe the low risk of non-CVD in patients with zero CAC. Indeed, Handy et 
al reported low rates of incident cancer, chronic kidney disease, chronic 
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obstructive pulmonary disease, hip fracture, and dementia-related 
hospitalizations in MESA.15 This is consistent with the understanding that CAC
serves as integrator of not only most upstream risk exposures, but also of 
individual vulnerability to their effects. Patients with CAC=0 and particularly 
those with CAC=0 over time26,27 represent a unique group of overall “healthy 
agers” deserving further study.
A CAC score of 1-10 (as compared to CAC=0) was associated with a 
multivariable-adjusted increased risk of death only in younger adults, while 
associations were attenuated after risk factor adjustment and became non-
significant in older age groups. This highlights the importance of considering 
not only absolute but also relative scores (within age and sex strata) when 
interpreting CAC burden.28 While in elderly individuals a CAC score of 1-10 
represents a relatively low burden within the CAC score distribution for this 
age group1,28 (e.g., below the 25th percentile of the CAC distribution for men 
ages 75-84 years of all four US racial/ethnic groups included in MESA28) the 
same score in a 35-year-old individual identifies a patient at increased risk of
events compared to same age and sex peers. Our findings suggest that 
early, aggressive lifestyle interventions in adults <40 years of age with any 
detectable CAC may be highly beneficial. Detection of higher CAC burden 
(i.e., CAC>10) particularly at young adult ages should trigger the 
consideration of these and additional pharmacologic interventions even more
strongly.
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Study Strengths
Strengths of the present study include large sample size, long follow-
up, and ascertainment of cause-specific mortality. These also allowed us to 
examine additional causes of death including stroke, heart failure, and 
pulmonary disease. An additional strength and novel contribution to the 
CAC=0 literature is the use of competing risk Fine and Gray modeling, which 
provides more accurate estimates of cause-specific risk in the presence of 
competing events. 
Study Limitations
There are also several limitations to our study. First, this was a clinical 
population of asymptomatic patients referred for CAC scoring, as opposed to 
other non-selected cohorts such as MESA, which are composed ofvolunteers 
from the community. While this may reduce generalizability of our results to 
certain unselected populations, our study should be highly generalizable to 
patients commonly referred for CAC scoring in clinical practice. In addition, 
inclusion of a mostly White patient population in the CAC Consortium may 
limit generalizability of the present findings to other racial/ethnic groups.
Second, information on treatment initiation after CAC scoring was not 
available. While a limitation, subsequent treatment with pharmacotherapies 
such as statins would be generally expected to yield a conservative bias in 
the CHD/CVD analyses, as patients with CAC>0 would be more likely to be 
treated with those therapies, reducing their likelihood of developing incident 
CHD/CVD events and death.
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Third, consistent with the changing epidemiology of CVD vs. cancer 
mortality,29 there were likely cohort effects within our broad study period, 
with higher CVD death rates in patients enrolled earlier in our study. This 
likely explains, at least partly, why cumulative annual CHD and CVD 
mortality in CAC=0 drifted down with time over our study, while cancer 
mortality modestly rises. 
Fourth, it is possible that some CAC=0 patients included in the CAC 
Consortium had been referred for CT assessment for other, non-coronary 
health concerns, their CAC score being assessed as part of the same exam. 
This would explain the counterintuitive, slightly higher death rates 
(particularly cancer death) observed in CAC=0 as compared to CAC 1-10 
patients during the first year of follow-up. This would have yielded a 
conservative bias when comparing CAC=0 patients (which would be at 
increased risk of death) to those with minimal CAC.
Finally, there were likely some missed deaths in the CAC Consortium. 
Our prior analyses have suggested that mortality rates may be 15-30% 
higher than we report, due to limitations inherent in vital status 
ascertainment in the US.16 However, this phenomenon should be non-
differential across causes of death, which would be expected to bias the 
results towards the null. Moreover, even accounting for missed events, 
patients with CAC=0 would still have a highly favorable prognosis (<3 deaths
per 1000 patient-years).
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Conclusions
In conclusion, we have shown that zero CAC, which is a frequent 
finding, is associated with stably low rates of CHD and CVD mortality over 
12-year follow-up, with cancer as the predominant (twice as likely) cause 
among the infrequent deaths in these patients. Our results support the 
emerging consensus that CAC=0 represents a unique population with highly 
favorable all-cause prognosis, who may be considered for more flexible 
treatment goals in primary prevention. On the other hand, younger 
individuals <40 years with minimal CAC 1-10 are at increased risk, and 
should be considered a distinct risk group. At any age, a CAC score >10 is 
associated with a markedly increased risk of death from any cause compared
to CAC=0 individuals, with CVD death more common than cancer death. 
Further research with even longer follow-up is needed to better understand 
the mechanisms underlying the “healthy aging” observed in CAC=0 patients,
as well as their lifetime trajectory. 
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FIGURE LEGENDS
Figure 1. Incidence proportion of all-cause and cause-specific death events 
during follow-up, by baseline CAC score.
Results are presented in %. 
Abbreviations: CAC = coronary artery calcium; CHD = coronary heart 
disease; CVD = cardiovascular disease
Figure 2. Distribution of causes of death by baseline CAC score. 
Results are presented in %, among participants experiencing death during 
follow-up.
Abbreviations: CAC = coronary artery calcium; CHD = coronary heart 
disease; CVD = cardiovascular disease
Figure 3. Cumulative incidence rates of all-cause mortality during follow-up,
by baseline CAC score.
Results are presented as cumulative incidence rates between baseline and 
up to each year of follow-up, per 1000 person-years. The X axis presents 
years of follow-up.
Abbreviations: CAC = coronary artery calcium
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Figure 4. Cumulative incidence rates of CVD death and cancer death during 
follow-up, by baseline CAC score.
Results are presented as cumulative incidence rates between baseline and 
up to each year of follow-up, per 1000 person-years. The X axis presents 
years of follow-up.
Abbreviations: CAC = coronary artery calcium; CVD = cardiovascular disease
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TABLES
Table 1. Baseline characteristics of the study participants.
Total
N=66,636
CAC
=0
N=29,757
1-10
N=7,808
>10
N=29,071
Age 54.4 (10.6) 49.9 (9.2) 52.7 (9.3) 59.5 (10.0)
Women
22,003
(33.0)
13,230
(44.5)
2,153
(27.6)
6,620
(22.8)
Race (N=42,964) 
     Non-Hispanic 
White
38,277
(89.1)
16,933
(88.7)
4,308
(87.5)
17,036
(89.9)
     Asian 1,621 (3.8) 794 (4.2) 181 (3.7) 646 (3.4)
     African-
American
977 (2.3) 429 (2.3) 140 (2.8) 408 (2.2)
     Hispanic 1,349 (3.1) 620 (3.3) 188 (3.8) 541 (2.9)
Hypertension
20,625
(31.0)
6,782
(22.8)
2,291
(29.3)
11,552
(39.7)
Diabetes 4,503 (6.8) 1,163 (3.9) 464 (5.9) 2,876 (9.9)
Dyslipidemia
37,861
(56.8)
15,112
(50.8)
4,466
(57.2)
18,283
(62.9)
Current Smoking 6,400 (9.6) 2,646 (8.9) 718 (9.2)
3,036
(10.4)
Family History of 
CHD
30,721
(45.6)
13,567
(45.6)
3,719
(47.6)
13,435
(46.2)
Number of Risk 
Factors
1.5 (1.0) 1.3 (1.0) 1.5 (1.0) 1.7 (1.0)
10-Year ASCVD 
Risk*
4.4 (1.9,
9.2)
2.4 (1.2,
4.7)
4.0 (2.0,
7.5)
7.9 (4.1,
14.8)
ASCVD Risk* 
Categories
     <5%
36,793
(55.2)
22,882
(76.9)
4,688
(60.0)
9,223
(31.7)
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     5-7.5%
8,939
(13.4)
3,181
(10.7)
1,163
(14.9)
4,595
(15.8)
     7.5-20%
15,665
(23.5)
3,264
(11.0)
1,679
(21.5)
10,722
(36.9)
     >20%
5,239
(7.86)
430 (1.45) 278 (3.56) 4,531
(15.6)
* 10-Year ASCVD risk estimated using the American College of Cardiology / 
American Heart Association Pooled Cohort Equations
Categorical variables presented as number (percentage), and continuous 
variables presented as mean (standard deviation) or median (interquartile 
range). All P values for the comparison across CAC categories <0.001, 
except for family history of CHD (0.01)
Abbreviations: ASCVD = atherosclerotic cardiovascular disease risk; CAC = 
coronary artery calcium; CHD = coronary heart disease
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Table 2. Associations between baseline CAC burden, all-cause and cause-
specific mortality during follow-up. 
Model 1 Model 2 Model 3
All-cause death
     CAC=0 (Ref.) 1.00 1.00 1.00
     CAC 1-10 1.39 (1.19, 1.62) 1.13 (0.94, 1.38) 1.04 (0.89, 1.22)
     CAC>10 4.16 (3.80, 4.55) 1.75 (1.54, 1.99) 1.63 (1.48, 1.81)
CVD death
     CAC=0 (Ref.) 1.00 1.00 1.00
     CAC 1-10 1.70 (1.23, 2.33) 1.26 (0.84, 1.89) 1.22 (0.88, 1.68)
     CAC>10 6.79 (5.61, 8.23) 2.65 (2.03, 3.45) 2.31 (1.88, 2.85)
CHD death
     CAC=0 (Ref.) 1.00 1.00 1.00
     CAC 1-10 1.47 (0.87, 2.46) 0.87 (0.43, 1.79) 1.00 (0.59, 1.68)
     CAC>10
9.16 (6.86,
12.23)
3.61 (2.39, 5.45) 2.83 (2.07, 3.86)
Cancer death
     CAC=0 (Ref.) 1.00 1.00 1.00
     CAC 1-10 1.11 (0.87, 1.41) 0.83 (0.61, 1.13) 0.88 (0.69, 1.12)
     CAC>10 2.70 (2.36, 3.10) 1.14 (0.94, 1.39) 1.19 (1.02, 1.40)
Results presented as hazard ratios from Cox proportional hazards regression 
analyses (all-cause death analyses), and subdistribution hazard ratios from 
Cox proportional hazards regression analyses accounting for competing risks
(cause-specific death analyses)
Model 1 was unadjusted; Model 2 adjusted for age and sex; Model 3 further 
adjusted for hypertension, hyperlipidemia, family history of CHD, diabetes, 
and current smoking status.
Abbreviations: CVD = cardiovascular disease; CAC = coronary artery 
calcium; CHD = coronary heart disease; Ref. = reference
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Table 3. Associations between baseline CAC burden, all-cause and cause-
specific mortality during follow-up, by sex. 
Model 1 Model 2 Model 3
Women (N=22,003)
All-cause death
     CAC=0 (Ref.) 1.00 1.00 1.00
     CAC 1-10 1.77 (1.39, 2.25) 1.17 (0.92, 1.49) 1.14 (0.90, 1.46) 
     CAC>10 4.77 (4.16, 5.48) 1.94 (1.67, 2.25) 1.80 (1.54, 2.10)
CVD death
     CAC=0 (Ref.) 1.00 1.00 1.00
     CAC 1-10 2.24 (1.33, 3.80) 1.36 (0.79, 2.33) 1.30 (0.76, 2.21) 
     CAC>10
8.99 (6.63,
12.18)
2.92 (2.10, 4.04) 2.57 (1.87, 3.54) 
CHD death
     CAC=0 (Ref.) 1.00 1.00 1.00
     CAC 1-10 1.73 (0.70, 4.28) 1.00 (0.39, 2.52) 0.95 (0.38, 2.41) 
     CAC>10
9.66 (6.03,
15.47)
2.80 (1.70, 4.64) 2.46 (1.50, 4.05) 
Cancer death
     CAC=0 (Ref.) 1.00 1.00 1.00
     CAC 1-10 1.50 (1.05, 2.14) 1.12 (0.78, 1.61) 1.10 (0.77, 1.58)
     CAC>10 2.82 (2.29, 3.47) 1.42 (1.12, 1.80) 1.36 (1.07, 1.73)
Men (N=44,633)
All-cause death
     CAC=0 (Ref.) 1.00 1.00 1.00
     CAC 1-10 1.30 (1.06, 1.56) 1.30 (1.06, 1.56) 0.95 (0.78, 1.17) 
     CAC>10 4.25 (3.76, 4.80) 4.25 (3.76, 4.80) 1.50 (1.31, 1.71) 
CVD death
     CAC=0 (Ref.) 1.00 1.00 1.00
     CAC 1-10 1.48 (0.99, 2.21) 1.48 (0.99, 2.21) 1.08 (0.72, 1.61) 
     CAC>10 6.1 (4.76, 7.82) 6.1 (4.76, 7.82) 2.02 (1.55, 2.63) 
CHD death
     CAC=0 (Ref.) 1.00 1.00 1.00
     CAC 1-10 1.34 (0.71, 2.53) 1.34 (0.71, 2.53) 0.98 (0.52, 1.84)
     CAC>10
8.77 (6.04,
12.73) 
8.77 (6.04,
12.73) 
2.88 (1.94, 4.26)
Cancer death
     CAC=0 (Ref.) 1.00 1.00 1.00
     CAC 1-10 1.01 (0.73, 1.41) 1.01 (0.73, 1.41) 0.76 (0.55, 1.06)
     CAC>10 2.99 (2.48, 3.61) 2.99 (2.48, 3.61) 1.10 (0.89, 1.36)
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Results presented as hazard ratios from Cox proportional hazards regression 
analyses (all-cause death analyses), and subdistribution hazard ratios from 
Cox proportional hazards regression analyses accounting for competing risks
(cause-specific death analyses)
Model 1 was unadjusted; Model 2 adjusted for age; Model 3 further adjusted 
for hypertension, hyperlipidemia, family history of CHD, diabetes, and 
current smoking status.
Abbreviations: CVD = cardiovascular disease; CAC = coronary artery 
calcium; CHD = coronary heart disease; Ref. = reference
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Table 4. Associations between baseline CAC burden, all-cause and cause-
specific mortality during follow-up, by age strata. 
<40 years
(N=4,855)
40-50
years
(N=17,802
)
50-60
years
(N=24,838
)
60-70
years
(N=13,418
)
≥70 years
(N=5,723)
All-cause death
     CAC=0 
(Ref.)
1.00 1.00 1.00 1.00 1.00
     CAC 1-10
2.91 (1.41,
6.00) 
0.80 (0.52,
1.23) 
1.20 (0.92,
1.58) 
0.98 (0.74,
1.31) 
0.97 (0.68,
1.40)
     CAC>10
2.90 (1.36,
6.21)  
1.81 (1.37,
2.38) 
1.77 (1.47,
2.13) 
1.43 (1.19,
1.72) 
1.80 (1.44,
2.25) 
CVD death
     CAC=0 
(Ref.)
1.00 1.00 1.00 1.00 1.00
     CAC 1-10
4.45 (1.34,
14.85) 
1.17 (0.56,
2.42) 
1.18 (0.59,
2.34) 
1.07 (0.57,
2.01) 
1.15 (0.59,
2.26) 
     CAC>10
3.88 (0.92,
16.37) 
1.87 (1.11,
3.16) 
3.17 (2.07,
4.86) 
2.11 (1.39,
3.19) 
2.33 (1.52,
3.56)
CHD death
     CAC=0 
(Ref.)
1.00 1.00 1.00 1.00 1.00
     CAC 1-10
1.25 (0.14,
10.91) 
1.67 (0.57,
4.91) 
1.74 (0.66,
4.58) 
0.42 (0.12,
1.47) 
0.66 (0.21,
2.09) 
     CAC>10
4.12 (0.66,
25.85) 
2.97 (1.32,
6.69) 
5.08 (2.68,
9.63) 
1.89 (1.08,
3.31)
2.43 (1.33,
4.46)
Cancer death
     CAC=0 
(Ref.)
1.00 1.00 1.00 1.00 1.00
     CAC 1-10 - 0.76 (0.34, 0.91 (0.62, 0.88 (0.58, 0.78 (0.42,
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1.70) 1.35) 1.34) 1.45) 
     CAC>10
1.64 (0.14,
19.00) 
1.34 (0.79,
2.23) 
1.08 (0.82,
1.41) 
1.07 (0.82,
1.40) 
1.23 (0.84,
1.78)
Results presented as hazard ratios from Cox proportional hazards regression 
analyses (all-cause death analyses), and subdistribution hazard ratios from 
Cox proportional hazards regression analyses accounting for competing risks
(cause-specific death analyses)
All analyses adjusted for sex, hypertension, hyperlipidemia, family history of 
CHD, diabetes, and current smoking status.
Abbreviations: CVD = cardiovascular disease; CAC = coronary artery 
calcium; CHD = coronary heart disease; Ref. = reference
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FIGURES
Figure 1. Incidence proportion of all-cause and cause-specific death events 
during follow-up, by baseline CAC score.
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Figure 2. Distribution of causes of death among participants dying during 
follow-up, by baseline CAC score. 
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Figure 2C. Baseline CAC>10
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Figure 3. Cumulative incidence rates of all-cause mortality during follow-up,
by baseline CAC score.
Figure 3A. Cumulative incidence rates of all-cause mortality for CAC=0, CAC 
1-10 and CAC >10.
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Figure 3B. Cumulative incidence rates of all-cause mortality for CAC=0 and 
CAC 1-10 using an alternative Y axis scale.
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Figure 4. Cumulative incidence rates of CVD death and cancer death during 
follow-up, by baseline CAC score.
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SUPPLEMENTARY METHODS
Risk Factor Definitions in the CAC Consortium
Hypertension was considered present if there was a prior diagnosis of 
hypertension or treatment with anti-hypertensive therapy. Blood pressure 
taken at the time of CT scanning was not used to override diagnoses of 
hypertension.
Dyslipidemia was defined as a prior diagnosis of primary 
hyperlipidemia (LDL-C >160 mg/dL), prior diagnosis of dyslipidemia 
(elevated triglycerides >150 mg/dL and/or low HDL-C <40 mg/dL in men and
<50 mg/dL in women), or treatment with any lipid-lowering drug.
For the present analysis, current smoking status was considered 
present or absent. 
Diabetes was defined as a prior diagnosis of diabetes or treatment with
oral hypoglycemic drugs or insulin. 
Family history of CHD was predominantly determined by the presence 
of a first degree relative with a history of CHD, however one site (11% of 
patients) used a definition of premature family history (<55 years in old in a 
male relative and <65 years old in a female relative).  
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SUPPLEMENTARY TABLES
Supplementary Table S1. Associations between baseline CAC burden and 
other causes of death. 
Model 1 Model 2 Model 3
Stroke death
     CAC=0 (Ref.) 1.00 1.00 1.00
     CAC 1-10 1.94 (0.94, 4.03) 1.52 (0.73, 3.18) 1.51 (0.72, 3.16) 
     CAC>10 6.22 (3.92, 9.86) 2.42 (1.45, 4.03) 2.30 (1.38, 3.83) 
Heart failure death
     CAC=0 (Ref.) 1.00 1.00 1.00
     CAC 1-10
8.61 (2.23,
33.25) 
6.07 (1.51,
24.38) 
5.89 (1.49,
23.39) 
     CAC>10
13.91 (4.31,
44.91) 
4.45 (1.23,
16.18) 
3.91 (1.09,
13.98) 
Other circulatory death
     CAC=0 (Ref.) 1.00 1.00 1.00
     CAC 1-10 1.38 (0.79, 2.40) 1.09 (0.62, 1.92) 1.07 (0.61, 1.88) 
     CAC>10 3.85 (2.78, 5.33) 1.75 (1.22, 2.52) 1.62 (1.12, 2.33) 
Non-CVD death
     CAC=0 (Ref.) 1.00 1.00 1.00
     CAC 1-10 1.31 (1.10, 1.57) 1.03 (0.86, 1.23) 1.03 (0.86, 1.23)
     CAC>10 3.40 (3.07, 3.77) 1.52 (1.36, 1.71) 1.46 (1.30, 1.64)
Pulmonary 
death
     CAC=0 (Ref.) 1.00 1.00 1.00
     CAC 1-10 3.24 (1.58, 6.65) 2.22 (1.08, 4.59) 2.22 (1.08, 4.59) 
     CAC>10
9.11 (5.43,
15.29) 
2.66 (1.53, 4.61) 2.46 (1.41, 4.28) 
Results presented as subdistribution hazard ratios from Cox proportional 
hazards regression analyses accounting for competing risks.
Model 1 was unadjusted; Model 2 adjusted for age and sex; Model 3 further 
adjusted for hypertension, hyperlipidemia, family history of CHD, diabetes, 
and current smoking status.
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Abbreviations: CVD = cardiovascular disease; CAC = coronary artery 
calcium; CHD = coronary heart disease; Ref. = reference
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